Status of Clinical Application of Yufeng Ningxin Preparations and the Meta-Analysis of Its Efficacy and Safety in the Treatment of Cardiovascular and Cerebrovascular Diseases

愈风宁心制剂临床应用现状及治疗心脑血管疾病有效性和安全性的Meta分析

Objective The objective of this study was to analyze the status of the clinical application of Yufeng Ningxin(YFNX)preparations and systematically evaluate their efficacy and safety in the treatment of cardiovascular and cerebrovascular diseases.Methods Through searching databases of China National Knowledge Infrastructure,Wanfang,SinoMed,VIP,PubMed,Embase,and the Cochrane Library,the literature of clinical research on YFNX preparations in treating malignant tumors of cardiovascular and cerebrovascular diseases from the establishment of the databases to February 2021 was collected.The clinical randomized controlled trials and case-control studies of cardiovascular and cerebrovascular diseases treated with these preparations were analyzed.Two reviewers independently screened literature,extracted data,and assessed the risk of bias in the included studies,and meta analysis was performed by using ReMan 5.3 software to analyze the eficacy and safety of YFNX preparations in the treatment of cardiovascular and cerebrovascular diseases.Results A total of 29 clinical studies were finally included.The dosage forms were dropping plls,tablets,capsules,and granules.The preparations were used for the treatment of coronary heart disease,hypertension,neuropathic headache,etc.This study systematically evaluated the efficacy and safety of YFNX preparations in the treatment of coronary heart disease,hypertension,and nervous headache.A total of 1,162 cases were included in 13 studies,582 cases of the YFNX preparation group and 580 cases of the Western medicine group.The results of meta-analysis showed that the clinical efficacy of YFNX preparations combined with the Western medicine group in the treatment of coronary heart disease and hypertension,improving electrocardiogram and reducing the frequency and duration of angina attacks,was better than that of the simple Western medicine group,and the difference was statistically significant.Conclusion YFNX preparations are effective for coronary heart disease,hypertension,and neuropathic headache,and the adverse reactions are few.

目的:分析愈风宁心(yu feng ning xin,YFNX)制剂临床应用现状,并系统评价YFNX制剂治疗心脑血管疾病的有效性和安全性。方法:计算机检索中国知网、万方数据库、中国生物医学文献数据库及PubMed、Embase、The Cochrane Library数据库,搜集关于YFNX制剂的临床研究相关文献,检索时限均为建库至2021年02月,提取相关资料分析YFNX制剂的临床应用现状。选取该药治疗心脑血管疾病的临床随机对照试验和病例对照研究,由2位评价员独立筛选文献、提取资料并评价纳入文献的方法学质量,采用RevMan 5.3软件进行Meta分析考察YFNX制剂治疗心脑血管疾病有效性和安全性。结果:共纳入29篇涉及YFNX制剂的临床研究,剂型为滴丸、片剂、胶囊、冲剂,用于治疗冠心病、高血压、神经性头痛等多种临床病证。纳入13个研究系统评价YFNX制剂在冠心病、高血压、神经性头痛的有效性和安全性,共1162例病例,其中YFNX制剂组582例,西药组580例。Meta分析结果显示,与单纯西药组相比,YFNX制剂+西药/YFNX制剂治疗可明显提高冠心病、高血压、神经性头痛的临床疗效,改善冠心病的心电图,减少心绞痛及头痛的发作次数,缩短心绞痛及头痛的持续时间,降低神经性头痛的头痛评分,差异具有统计学意义(P<0.05)。结论:YFNX制剂对冠心病、高血压、神经性头痛有较好的临床疗效,且不良反应少。